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Abstract
Excitatory amino acid transporter 2 (EAAT2) is the major glutamate transporter and functions to
remove glutamate from synapses. A thiopyridazine derivative has been found to increase EAAT2
protein levels in astrocytes. A structure-activity relationship study revealed that several
components of the molecule were required for activity, such as the thioether and pyridazine.
Modification of the benzylthioether resulted in several derivatives (7–13, 7–15 and 7–17) that
enhanced EAAT2 levels by > 6 fold at concentrations < 5 μM after 24 h. In addition, one of the
derivatives (7–22) enhanced EAAT2 levels 3.5 – 3.9 fold after 24 h with an EC50 of 0.5 μM.
Glutamate is a major neurotransmitter in the mammalian central nervous system (CNS) and
essential for normal brain function including cognition, memory, and learning. However, the
extracellular concentration of glutamate must remain below excitotoxic levels (~ 1 μM) to
avoid overstimulation of glutamate receptors, leading to neuronal damage or death.1
Excitotoxicity has been associated with multiple acute neurological conditions such as
ischemic stroke, epilepsy, and trauma, as well as chronic adult-onset neurodegenerative
disorders such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).2–6 One
potential approach to preventing excitotoxicity is to enhance glutamate reuptake. Excitatory
amino acid transporter 2 (EAAT2) is the major glutamate transporter and functions to
remove glutamate from synapses.7 An increase in EAAT2 protein expression and function
may provide a means to prevent insufficient glutamate reuptake and consequently reduce
neuronal damage.
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In an effort to identify small molecules that can increase EAAT2 protein expression, a high-
throughput screen of approximately 140,000 compounds was previously conducted in our
laboratories using a cell-based enzyme-linked immunosorbent assay.8 The hits identified
from this screening provide starting points for further optimization in order to arrive at
pharmacologically useful molecules for studying the role of EAAT2 in excitotoxicity
induced neuronal injury and potentially as therapeutic agents.
The thiopyridazine 1 was confirmed to show a dose-dependent increase in EAAT2 protein
levels after 24 h exposure. Herein, we report the structure-activity relationship (SAR) study
of 1 for elevating EAAT2 protein levels.
Many of the pyridazine analogues utilized in the SAR study were prepared using the method
depicted in Scheme 1. Treatment of ketone 2 with glyoxylic acid (3) and K2CO3 gave 4,
which was used directly without purification. It was allowed to react with hydrazine in
acetic acid at 100 °C to yield the desired pyridazinone 5 as an off-white solid after
recrystallization from ethyl acetate.9 Direct alkylation of 5 gave 8 in good yields.
Intermediate 5 was also converted into pyridazinethione 6 in the presence of P2S5 in
pyridine at 120 °C.10 Alkylation of 6 provided 7, which could be subsequently oxidized to
sulfone 9 with 3-chloroperoxybenzoic acid (m-CPBA) in CH2Cl2.11
A series of additional analogues 14–17 was prepared using the methodology outlined in
Scheme 2. Recently, 2-pyridyl N-methyliminodiacetic acid (MIDA) boronate (10) has been
reported as an air-stable slow-release reagent with high cross-coupling efficiency even with
heteroaryl chlorides.12 Therefore, this material was used in palladium-mediated cross-couple
reactions with heteroaryl chlorides 11 – 13 to obtain 14 – 16, respectively. In the case of 13
transesterification occurred during the cross-coupling reaction to give the isopropyl ester 16,
which was then allowed to react with alkylamines in ethanol at 85 °C to generate amides 17.
Finally, several additional analogues designed to evaluate replacement of the pyridazine in 1
with phenyl and pyridyl moieties were prepared using the methodology outlined in Scheme
3. Suzuki coupling of 2-bromopyridine (18) with various boronic acids afforded 19 and
20.13 Treatment of 20 with P2S5 in pyridine at 120 °C provided 21 in 71% yield. Alkylation
of 21 with 2-methylbenzyl bromide in the presence of K2CO3 in DMF generated 22.
All of the derivatives of 1 were initially evaluated in PA-EAAT2 cells3 (a primary astrocyte
line stably expressing EAAT2 mRNAs) following compound (10 μM) incubation for 4 and
24 h before harvesting and measuring EAAT2 levels by Western blot analysis. The fold
increases in EAAT2 protein levels relative to DMSO controls are reported (Tables 1 – 4).
Replacement of the 2-pyridyl with 3-pyridyl (7–1, 7–5 and 7–8), 4-pyridyl (7–2, 7–9 and 7–
11) or phenyl (7–6) resulted in equal or reduced activity (Table 1). Removing either one or
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both of the nitrogen atoms in the pyridazine resulted in loss of activity (Table 2).
Collectively, these results suggested that both the 2-pyridyl and the pyridazine were required
for enhancing EAAT2 protein expression.
Next, the sulfur linker was examined (Table 3). Replacing the sulfur with oxygen generally
yielded less active derivatives. An analogue containing a NH linker (14) showed weaker
activity. Likewise, oxidation of the sulfur to a sulfone (9–1, 9–2, and 9–3) was also
detrimental. Finally, replacing the sulfur with an amide moiety (17–1 and 17–2) was not
tolerated. Collectively, these results indicated that the sulfur linker was optimal.
Finally, the benzyl group was examined (Table 4). Compared to 1, 2-chloro, 3-chloro and 2,
6-dichloro substitutions improved the potency by two-fold (7–7, 7–18 and 7–22), but 2, 3-
dichloro, 2,4-dichloro and 2, 5-dichloro analogues (7–19, 7–21 and 7–20) were equivalent to
1. In the case of fluorine substitutes, only the 2-fluoro and 2, 4-difluoro derivatives (7–23
and 7–16) demonstrated improved activity. 4-Fluoro, 2, 6-difluoro, and 2, 4, 6-trifluoro
analogues (7–24, 7–25, and 2–26) did not result in significant improvement. Replacement of
the halogens with methyls (7–4, 7–13, 7–17, and 7–30) gave increased potency. Compounds
containing 2-methyl substituted benzyl groups significantly increased EAAT2 protein level,
where as the 3- or 4-methylbenzyl derivatives (7–27 and 7–28) were less potent. Increasing
the tether length between the phenyl and the sulfur to an ethylene generally yielded more
potent analogues (7–15 and 7–31 verses 1 and 7–7, respectively) with one noted exception
(compare 7–32 to 7–4). However, truncating the linker resulting in a diarylthioether
decreased potency (7–29 verses 7–17). Interestingly, adding substitutes on the carbon linker
(7–14 and 7–33) increased activity about 3-fold. Finally, other changes gave compounds
with essentially the same potency as 1 (7–12, 7–36, and 6–1).
In order to further characterize twelve of the most active analogues from the initial
assessment, they were evaluated in a 6-point dose-response assay (0.1, 0.3, 1.0, 5.0, 10.0,
and 30.0 μM). The fold increases at 1 and 10 μM, as well as the EC50 values are
summarized in Table 5. In addition, these values were determined relative to two unrelated
proteins (e.g. β-actin and GAPDH). Several compounds (7–13, 7–17, 7–31 and 7–18) were
able to increase EAAT2 levels > 6-fold at 10 μM compared to β-actin or GAPDH, but with
EC50 values in the 2.6 – 3.3 μM range. Analog 7–22 demonstrated the lowest EC50 of 0.5
μM with a maximum increase of EAAT2 levels of 3- to 4-fold.
In summary, a series of pyridazine derivatives were synthesized and evaluated for increasing
EAAT2 protein levels. Several compounds were found to significantly increase EAAT2
protein levels (> 6 fold), such as 7–13, 7–15 and 7–17. Derivative 7–22 increased EAAT2
protein levels to a lower extent (3.5 – 3.9 fold), but with a lower EC50 value (0.5 μM). These
compounds will provide useful tools for further assessing the role of glutamate
excitotoxicity in cellular systems and potentially in animal models of acute and chronic
neurodegeneration. In addition, these probe molecules may also be beneficial in determining
the biological mechanisms for regulating EAAT2 levels.
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Scheme 1.
Reagents and conditions: (a) K2CO3, H2O; (b) NH2NH2, AcOH, 100 °C (20%); (c) P2S5,
pyridine, 120 °C (80%); (d) R2Br, K2CO3, DMF (90%); (e) MCPBA, CH2Cl2 (80%).
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Scheme 2.
Reagents and conditions: (a) Pd2(dba)3, XPhos, Cu(OAc)2, K2CO3, DMF/i-PrOH (4/1), 100
°C; (b) H2NR, ethanol, 85 °C (90%).
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Scheme 3.
Reagents and conditions: (a) Pd(PPh3)4, Na2CO3, CH3CN/H2O (1/1), 75 °C, 4-
benzylthiophenylboronic acid (54%); (b) Pd(PPh3)4, Na2CO3, CH3CN/H2O (1/1), 75 °C, 6-
hydroxypyridine-3-boronic acid pinacol ester (70%); (c) P2S5, pyridine, 120 °C (71%); (d)
2-methylbenzyl bromide, K2CO3, DMF (76%).
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Table 1
Effects of the modified pyridyl and benzyl substituent on EAAT2 protein levels
Compound R1 R2 Fold increase for EAAT2a
4 h 24 h
1 2-Py 2-Cl-6-F-Bn nab 2.0 ± 0.8
7–1 3-Py 2-Cl-6-F-Bn na 2.3 ± 0.8
7–2 4-Py 2-Cl-6-F-Bn na 1.9 ± 0.9
7–3 4-Me-Ph 2-Cl-6-F-Bn 1.2 ± 0.2 2.3 ± 0.7
7–4 2-Py 2-Me-Bn 1.7 ± 0.1 3.5 ± 0.3
7–5 3-Py 2-Me-Bn 1.5 ± 0.4 na
7–6 Ph 2-Me-Bn 1.1 ± 0.1 2.0 ± 0.4
7–7 2-Py 2-Cl-Bn 2.1 ± 1.4 4.0 ± 0.3
7–8 3-Py 2-Cl-Bn 1.2 ± 0.4 1.2 ± 0.3
7–9 4-Py 2-Cl-Bn 1.5 ± 0.2 1.7 ± 0.3
7–10 2-Py 4-Me-Bn 2.1 ± 1.1 2.6 ± 0.4
7–11 4-Py 4-Me-Bn 1.3 ± 0.1 2.4 ± 0.6
a
Compound concentration of 10 μM;
b
na = not active
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Table 3
Effects of modifications of the sulfur linker on EAAT2 protein levels
Compound X R Fold increase for EAAT2a
4 h 24 h
1 S 2-Cl-6-F-Bn nab 2.0 ± 0.8
8–2 O 2-Cl-6-F-Bn 1.1 ± 0.3 2.9 ± 0.4
7–4 S 2-Me-Bn 1.7 ± 0.1 3.5 ± 0.3
8–1 O 2-Me-Bn 2.0 ± 0.9 2.5 ± 0.5
7–13 S 2,6-di-Me-Bn na 6.5 ± 1.0
8–3 O 2,6-di-Me-Bn 2.1 ± 1.2 3.2 ± 1.4
7–14 S 1-(2-Cl-6-F-phenyl)ethyl 1.7 ± 0.9 5.5 ± 1.0
8–4 O 1-(2-Cl-6-F-phenyl)ethyl 1.6 ± 0.2 3.0 ± 0.7
7–15 S 2-(2-Cl-6-F-phenylethyl) 1.9 ± 0.7 6.7 ± 1.5
8–5 O 2-(2-Cl-6-F-phenylethyl) 2.2 ± 0.4 3.1 ± 1.2
7–16 S 2,4-di-F-Bn 2.4 ± 1.5 3.8 ± 0.8
8–6 O 2,4-di-F-Bn na 2.3 ± 0.6
7–17 S 2,4-di-Me-Bn 1.9 ± 0.8 6.4 ± 1.0
8–7 O 2,4-di-Me-Bn na 2.0 ± 0.9
6–1 S H na 2.0 ± 0.8
5–1 O H 1.5 ± 0.5 1.6 ± 1.0
14 NH 2-Me-Bn 1.7 ± 1.1 2.6 ± 0.5
9–1 SO2 2-Cl-6-F-Bn 1.4 ± 0.3 2.8 ± 0.4
9–2 SO2 2-Me-Bn 2.3 ± 0.4 1.1 ± 0.2
9–3 SO2 2-Cl-Bn 1.6 ± 0.3 na
17–1 CONH n-Pr na 1.2 ± 0.2
17–2 CONH 2-Me-Bn na 1.4 ± 0.2
a
Compound concentration of 10 μM;
b
na = not active
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Table 4
Effects of the benzyl group on EAAT2 protein levels
Compound R Fold increase for EAAT2a
4 h 24 h
1 2-Cl-6-F-Bn nab 2.0 ± 0.8
7–7 2-Cl-Bn 2.1 ± 1.4 4.0 ± 0.3
7–18 3-Cl-Bn 2.1 ± 0.3 4.1 ± 0.5
7–19 2,3-di-Cl-Bn na 2.4 ± 0.4
7–20 2,5-di-Cl-Bn 1.4 ± 0.1 2.5 ± 0.4
7–21 2,4-di-Cl-Bn 1.8 ± 0.5 na
7–22 2,6-di-Cl-Bn 1.5 ± 0.8 3.9 ± 0.4
7–23 2-F-Bn 2.2 ± 0.1 3.1 ± 0.2
7–24 4-F-Bn 2.5 ± 0.6 2.6 ± 0.3
7–16 2,4-di-F-Bn 2.4 ± 1.5 3.8 ± 0.8
7–25 2,6-di-F-Bn 2.1 ± 1.4 2.2 ± 0.7
7–26 2,4,6-tri-F-Bn 1.6 ± 1.0 2.4 ± 0.6
7–4 2-Me-Bn 1.7 ± 0.1 3.5 ± 0.3
7–27 3-Me-Bn 2.0 ± 0.2 2.8 ± 0.5
7–28 4-Me-Bn 2.1 ± 1.1 2.6 ± 0.4
7–29 2,4-di-Me-Ph 1.2 ± 0.3 2.2 ± 0.3
7–17 2,4-di-Me-Bn 1.9 ± 0.8 6.4 ± 1.0
7–13 2,6-di-Me-Bn na 6.5 ± 1.0
7–30 2,4,6-tri-Me-Bn 1.7 ± 0.3 4.7 ± 0.5
7–15 2-(2-Cl-6-F-phenylethyl) 1.9 ± 0.7 6.7 ± 1.5
7–31 2-(2-Cl-phenylethyl) 1.7 ± 0.2 4.8 ± 0.6
7–32 2-(2-Me-phenylethyl) 1.2 ± 0.3 2.8 ± 0.4
7–33 1-(1,2,3,4-tetrahydronaphthalenyl) na 5.3 ± 1.1
7–14 1-(2-Cl-6-F-phenyl)ethyl 1.7 ± 0.9 5.5 ± 1.0
7–34 2-Cl-4-F-Ph 1.3 ± 0.1 2.5 ± 0.7
7–35 2-Cl-4-F-Bn 1.6 ± 0.6 1.7 ± 0.4
7–12 Bn 1.3 ± 0.2 3.0 ± 0.5
7–36 Et 1.6 ± 0.7 1.9 ± 0.9
6–1 H na 2.0 ± 0.8
a
Compound concentration of 10 μM;
b
na = not active
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